White paper: Aseptic filling for personalized medicines | Vanrx
Aseptic filling for cell therapies, gene therapies, viral vectors and other personalized medicines.

White paper: Aseptic filling for personalized medicines

February 16, 2018 - cell therapy, Gene therapy, White Paper

Vanrx Pharmasystems has released Aseptic Filling for Personalized Medicines, a white paper that reviews how new agile filling technology can change the manufacturing of cell and gene therapies.

Aseptic Filling for Personalized Medicines describes a solution for the aseptic filling of cell and gene therapies, immuno-oncology, mRNA and other modalities where manufacturing creates a therapy for a single patient. New technologies that automate the production of personalized medicines will be critical to both their clinical efficacy and commercial viability.

The solution introduced is a gloveless robotic isolator, a machine that performs automated vial filling and closure for small batches of sterile injectables. These tasks are performed within the small space of a completely closed isolator that maintains aseptic conditions. This new technology provides many benefits, including:

  • Cost-effectiveness: build clinical and development filling capacity at a lower cost and in less time.
  • Agility: fill up to four products in a single day. Can fill 2R-50R nested vials with toolless changeover and decontamination in 15 minutes.
  • Standard design: allows companies can scale quickly to meet commercial demand.

Vanrx was founded by experts in biopharmaceutical development and manufacturing. The company designs and manufactures Aseptic Filling Workcells—gloveless robotic isolators.

About Vanrx Pharmasystems
Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies. For more information, visit www.vanrx.com.

 

Fill out my online form.

Articles you may want to read

What do NGS and CRISPR-Cas9 mean for the future of drug products?

The transition from blanket therapeutic approaches to customized treatments for a single patient is referred to as precision medicine. This article discusses two scientific tools and how they influence the future of precision medicine: Next-generation sequencing (NGS) and CRISPR-Cas9.

Go to article



White paper: A New Paradigm for Manufacturing Injectable Medicines

Vanrx's white paper “A New Paradigm for Manufacturing Injectable Medicines” details a solution that supports the flexible production of parenteral drug products. This solution resolves long-standing issues in aseptic production, while enabling manufacturers to bring drug products to market faster.

Go to article